The IAVI DataSpace integrates a unique clinical, genetic and biological dataset from a sub-Saharan cohort of 1,019 participants (Protocol C) identified and enrolled with early HIV infection (including their suspected transmitting partners, where available). It contains numerous datasets related to Protocol C, including details of study participants, 9561 clinical visits and 154,436 donated samples (as of December, 2018).
Check out a recent publication on KIRs in HIV that was supported by Protocol C samples
Researchers studied a well-characterized cohort of HIV-1 seroconverters from sub-Saharan Africa who were identified when seronegative and followed under Protocol C of the International AIDS Vaccine Initiative (IAVI). iKIR genes enhance the protective effect of HLA-B*57 on early set-point viral load and time to low CD4 count. The full paper is available in November 2018...
IAVI DataSpace website to be launched at HIVR4P 2018 in Madrid
IAVI will present the IAVI DataSpace at the 2018 HIVR4P annual event in Madrid. The IAVI DataSpace is a portal to gain entry to IAVI’s open-access data warehouse that builds on years of epidemiological, clinical, and immunological data generated by IAVI in partnership with Clinical Research Centers in Eastern and Southern Africa. This is an exciting...
IAVI recognized early on that to develop effective HIV vaccines for use throughout the world, it is essential to build partnerships and bolster capacity to conduct vaccine trials at the highest technical and ethical standards in developing countries, where the need for a vaccine is the greatest.
Today, a network of independent but interconnected research centers in five sub-Saharan African countries (Kenya, Rwanda, South Africa, Uganda and Zambia), as well as India, the UK and USA, play a central role in IAVI’s vaccine development program, testing HIV vaccine candidates and conducting epidemiological studies to inform the design of candidates and provide baseline information for future efficacy trials.
This partnership-based approach emphasizes building capacity by training local researchers and developing the infrastructure required for such research. Investigators within this network are linked to scientific consortia—such as the Center for HIV/AIDS Vaccine Immunology and the Neutralizing Antibody Consortium—and collaborate closely with IAVI researchers.
This program is made possible by the support of the American People through the United States Agency for International Development (USAID) and the US President’s Emergency Plan for AIDS Relief (PEPFAR). The content of this website is the sole responsibility of IAVI and does not necessarily reflect the views of USAID, PEPFAR, or the United States Government.